Zura Bio Stock Jumps 19.9% on Third-Quarter Results and Trial Timing Update
The company reported a wider third-quarter net loss and said its TibuSHIELD data remains on track for the fourth quarter of 2026.
Key points
- Zura Bio rose 19.9% to $4.27 on Tuesday, Oct. 27, 2026; no specific cause was tied to the move in the filings.
- Q3 2026 net loss was $25.8 million, or $0.20 per share, versus $18.0 million, or $0.21 per share, a year earlier.
- Cash and equivalents were $187.7 million as of Sept. 30, 2026, which the company says covers operations through at least 2028.
- TibuSHIELD topline data remains on track for Q4 2026.
Zura Bio Ltd (Nasdaq: ZURA) rose 19.9% on Tuesday, Oct. 27, 2026, closing at $4.27 from a previous close of $3.56, while the S&P 500 ETF (SPY) gained 0.56% that session. Trading volume was about 1.5 times its typical level. The company's own filings are the only news the sources give for the session, and they do not state a reason for the advance.
The company filed an 8-K at 7:40 a.m. ET that included its third-quarter 2026 results and a corporate presentation furnished under Regulation FD. The press release accompanying the filing reiterated timing for its tibulizumab studies: topline data from the TibuSHIELD study in hidradenitis suppurativa remains on track for the fourth quarter of 2026, and TibuSURE data in systemic sclerosis remains on track for the first half of 2027.
Enrollment and timelines
Both Phase 2 studies have completed enrollment. TibuSHIELD randomized 247 participants and TibuSURE randomized 91, each exceeding its target, according to the press release. A third Phase 2 study, NEXUS-PMR in polymyalgia rheumatica, remains on track to start by year-end 2026.
Losses and cash
Net loss for the quarter was $25.8 million, or $0.20 per share, compared with $18.0 million, or $0.21 per share, a year earlier. Research and development expenses rose to $19.5 million from $11.9 million, which the company attributed to its Phase 2 programs and NEXUS-PMR start-up work. General and administrative expenses were $9.3 million, up from $7.6 million. Cash and cash equivalents were $187.7 million as of Sept. 30, 2026, which the company says will fund planned operations through at least the end of 2028.
The filings do not link the share-price move to any specific item in the results.
Sources
Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
More on Zura Bio
ZURA page →Filings, figures and price history are on the Zura Bio page.